SEC Form 4 · accession 0001209191-19-012005
VERTEX PHARMACEUTICALS INC / MA · VRTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Michael Parini
Officer — EVP, CL&AO
Period of report
Feb 19, 2019
Accepted (ET)
Feb 21, 2019 · 4:26 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000875320
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2,F3 | Feb 19, 2019 | S | 4,624 | $186.79 | D | 36,003 | D | |
| Common StockF3,F4 | Feb 19, 2019 | S | 600 | $187.42 | D | 35,403 | D | |
| Common StockF3,F5 | Feb 19, 2019 | S | 400 | $188.54 | D | 35,003 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1.
- F2Open market sales reported on this line occurred at a weighted average price of $186.79 (range $186.09 to $187.05).
- F3Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- F4Open market sales reported on this line occurred at a weighted average price of $187.42 (range $187.12 to $187.96).
- F5Open market sales reported on this line occurred at a weighted average price of $188.54 (range $188.36 to $188.85).